Enhabit (EHAB) Competitors

$13.80 0.00 (0.00%)

Closing price 05/14/2026

Extended Trading

$13.80 0.00 (0.00%)

As of 05/14/2026 05:41 PM Eastern

EHAB vs. GRAL, HTFL, DFTX, ADUS, and SGRY

Should you buy Enhabit stock or one of its competitors? MarketBeat compares Enhabit with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enhabit include GRAIL (GRAL), Heartflow (HTFL), Definium Therapeutics (DFTX), Addus HomeCare (ADUS), and Surgery Partners (SGRY). These companies are all part of the "healthcare" industry.

How does Enhabit compare to GRAIL?

Enhabit (NYSE:EHAB) and GRAIL (NASDAQ:GRAL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Enhabit has a net margin of -0.30% compared to GRAIL's net margin of -253.22%. Enhabit's return on equity of 7.24% beat GRAIL's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enhabit	-0.30%	7.24%	3.48%
GRAIL	-253.22%	-16.42%	-14.34%

Enhabit currently has a consensus target price of $13.57, indicating a potential downside of 1.66%. GRAIL has a consensus target price of $67.88, indicating a potential upside of 11.29%. Given GRAIL's stronger consensus rating and higher possible upside, analysts plainly believe GRAIL is more favorable than Enhabit.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enhabit	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
GRAIL	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38

Enhabit has a beta of 1.26, indicating that its stock price is 26% more volatile than the broader market. Comparatively, GRAIL has a beta of 3.03, indicating that its stock price is 203% more volatile than the broader market.

In the previous week, Enhabit had 2 more articles in the media than GRAIL. MarketBeat recorded 4 mentions for Enhabit and 2 mentions for GRAIL. Enhabit's average media sentiment score of 0.41 beat GRAIL's score of 0.35 indicating that Enhabit is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enhabit	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GRAIL	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enhabit has higher revenue and earnings than GRAIL. Enhabit is trading at a lower price-to-earnings ratio than GRAIL, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enhabit	$1.06B	0.67	-$4.60M	-$0.09	N/A
GRAIL	$147.17M	17.79	-$408.35M	-$10.37	N/A

Summary

Enhabit beats GRAIL on 8 of the 14 factors compared between the two stocks.

How does Enhabit compare to Heartflow?

Heartflow (NASDAQ:HTFL) and Enhabit (NYSE:EHAB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

In the previous week, Heartflow had 4 more articles in the media than Enhabit. MarketBeat recorded 8 mentions for Heartflow and 4 mentions for Enhabit. Heartflow's average media sentiment score of 0.51 beat Enhabit's score of 0.41 indicating that Heartflow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Heartflow	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enhabit	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Heartflow currently has a consensus price target of $37.00, indicating a potential upside of 39.10%. Enhabit has a consensus price target of $13.57, indicating a potential downside of 1.66%. Given Heartflow's stronger consensus rating and higher probable upside, equities research analysts clearly believe Heartflow is more favorable than Enhabit.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heartflow	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
Enhabit	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

Enhabit has a net margin of -0.30% compared to Heartflow's net margin of -58.42%. Enhabit's return on equity of 7.24% beat Heartflow's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heartflow	-58.42%	N/A	-20.02%
Enhabit	-0.30%	7.24%	3.48%

Enhabit has higher revenue and earnings than Heartflow. Enhabit is trading at a lower price-to-earnings ratio than Heartflow, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heartflow	$176.03M	13.03	-$116.79M	-$3.11	N/A
Enhabit	$1.06B	0.67	-$4.60M	-$0.09	N/A

Summary

Heartflow beats Enhabit on 7 of the 13 factors compared between the two stocks.

How does Enhabit compare to Definium Therapeutics?

Enhabit (NYSE:EHAB) and Definium Therapeutics (NASDAQ:DFTX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

27.9% of Definium Therapeutics shares are owned by institutional investors. 3.4% of Enhabit shares are owned by insiders. Comparatively, 2.3% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Enhabit has a beta of 1.26, suggesting that its stock price is 26% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the broader market.

Enhabit presently has a consensus target price of $13.57, indicating a potential downside of 1.66%. Definium Therapeutics has a consensus target price of $37.92, indicating a potential upside of 89.43%. Given Definium Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Definium Therapeutics is more favorable than Enhabit.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enhabit	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Definium Therapeutics had 6 more articles in the media than Enhabit. MarketBeat recorded 10 mentions for Definium Therapeutics and 4 mentions for Enhabit. Enhabit's average media sentiment score of 0.41 beat Definium Therapeutics' score of 0.00 indicating that Enhabit is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enhabit	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Definium Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Definium Therapeutics has a net margin of 0.00% compared to Enhabit's net margin of -0.30%. Enhabit's return on equity of 7.24% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enhabit	-0.30%	7.24%	3.48%
Definium Therapeutics	N/A	-100.30%	-69.22%

Enhabit has higher revenue and earnings than Definium Therapeutics. Enhabit is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enhabit	$1.06B	0.67	-$4.60M	-$0.09	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$2.49	N/A

Summary

Definium Therapeutics beats Enhabit on 9 of the 16 factors compared between the two stocks.

How does Enhabit compare to Addus HomeCare?

Enhabit (NYSE:EHAB) and Addus HomeCare (NASDAQ:ADUS) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability, media sentiment and risk.

95.4% of Addus HomeCare shares are held by institutional investors. 3.4% of Enhabit shares are held by insiders. Comparatively, 4.5% of Addus HomeCare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Enhabit presently has a consensus target price of $13.57, indicating a potential downside of 1.66%. Addus HomeCare has a consensus target price of $131.22, indicating a potential upside of 41.72%. Given Addus HomeCare's stronger consensus rating and higher probable upside, analysts clearly believe Addus HomeCare is more favorable than Enhabit.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enhabit	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

Addus HomeCare has higher revenue and earnings than Enhabit. Enhabit is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enhabit	$1.06B	0.67	-$4.60M	-$0.09	N/A
Addus HomeCare	$1.42B	1.22	$95.91M	$5.41	17.11

Enhabit has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market. Comparatively, Addus HomeCare has a beta of 0.92, meaning that its share price is 8% less volatile than the broader market.

In the previous week, Addus HomeCare had 9 more articles in the media than Enhabit. MarketBeat recorded 13 mentions for Addus HomeCare and 4 mentions for Enhabit. Enhabit's average media sentiment score of 0.41 beat Addus HomeCare's score of 0.26 indicating that Enhabit is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enhabit	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Addus HomeCare	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Addus HomeCare has a net margin of 6.89% compared to Enhabit's net margin of -0.30%. Addus HomeCare's return on equity of 9.80% beat Enhabit's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enhabit	-0.30%	7.24%	3.48%
Addus HomeCare	6.89%	9.80%	7.34%

Summary

Addus HomeCare beats Enhabit on 15 of the 17 factors compared between the two stocks.

How does Enhabit compare to Surgery Partners?

Surgery Partners (NASDAQ:SGRY) and Enhabit (NYSE:EHAB) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, media sentiment, valuation, earnings, analyst recommendations, profitability and dividends.

Surgery Partners has a beta of 1.99, indicating that its share price is 99% more volatile than the broader market. Comparatively, Enhabit has a beta of 1.26, indicating that its share price is 26% more volatile than the broader market.

Enhabit has lower revenue, but higher earnings than Surgery Partners. Enhabit is trading at a lower price-to-earnings ratio than Surgery Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgery Partners	$3.31B	0.54	-$77.90M	-$0.60	N/A
Enhabit	$1.06B	0.67	-$4.60M	-$0.09	N/A

Surgery Partners currently has a consensus price target of $22.18, suggesting a potential upside of 62.03%. Enhabit has a consensus price target of $13.57, suggesting a potential downside of 1.66%. Given Surgery Partners' stronger consensus rating and higher possible upside, analysts clearly believe Surgery Partners is more favorable than Enhabit.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgery Partners	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
Enhabit	1 Sell rating(s)	6 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.11

In the previous week, Enhabit had 2 more articles in the media than Surgery Partners. MarketBeat recorded 4 mentions for Enhabit and 2 mentions for Surgery Partners. Surgery Partners' average media sentiment score of 0.64 beat Enhabit's score of 0.41 indicating that Surgery Partners is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Surgery Partners	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enhabit	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enhabit has a net margin of -0.30% compared to Surgery Partners' net margin of -2.28%. Enhabit's return on equity of 7.24% beat Surgery Partners' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgery Partners	-2.28%	1.04%	0.41%
Enhabit	-0.30%	7.24%	3.48%

Summary

Surgery Partners and Enhabit tied by winning 7 of the 14 factors compared between the two stocks.

Get Enhabit News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EHAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EHAB vs. The Competition

Export

Metric	Enhabit	Medical Services Industry	Medical Sector	NYSE Exchange
Market Cap	$706.97M	$8.13B	$6.25B	$22.83B
Dividend Yield	N/A	3.12%	2.80%	4.11%
P/E Ratio	-153.33	20.55	20.79	29.48
Price / Sales	0.67	16.32	531.21	23.83
Price / Cash	7.04	80.78	43.09	24.68
Price / Book	1.22	5.49	9.81	4.61
Net Income	-$4.60M	$180.93M	$3.55B	$1.07B
7 Day Performance	0.04%	-1.54%	-2.07%	-1.81%
1 Month Performance	0.62%	-0.97%	-3.90%	-2.17%
1 Year Performance	30.07%	-0.18%	29.39%	20.97%

Enhabit Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EHAB Enhabit	2.5152 of 5 stars	$13.80 flat	$13.57 -1.7%	+29.6%	$706.97M	$1.06B	N/A	10,800	News Coverage Positive News
GRAL GRAIL	1.6631 of 5 stars	$61.98 +1.2%	$67.88 +9.5%	+52.1%	$2.63B	$147.17M	N/A	1,360
HTFL Heartflow	3.5382 of 5 stars	$29.42 +0.1%	$37.67 +28.0%	N/A	$2.53B	$176.03M	N/A	699	Earnings Report
DFTX Definium Therapeutics	2.4834 of 5 stars	$21.16 -1.1%	$37.92 +79.2%	+210.3%	$2.13B	N/A	N/A	40
ADUS Addus HomeCare	4.5891 of 5 stars	$98.49 +0.7%	$132.33 +34.4%	-17.0%	$1.83B	$1.42B	18.21	50,659	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:EHAB) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enhabit (EHAB) Competitors

EHAB vs. GRAL, HTFL, DFTX, ADUS, and SGRY

How does Enhabit compare to GRAIL?

Summary

How does Enhabit compare to Heartflow?

Summary

How does Enhabit compare to Definium Therapeutics?

Summary

How does Enhabit compare to Addus HomeCare?

Summary

How does Enhabit compare to Surgery Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EHAB vs. The Competition

Enhabit Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enhabit (EHAB) Competitors

EHAB vs. GRAL, HTFL, DFTX, ADUS, and SGRY

How does Enhabit compare to GRAIL?

Is EHAB or GRAL more profitable?

Do analysts rate EHAB or GRAL?

Which has more volatility & risk, EHAB or GRAL?

Does the media refer more to EHAB or GRAL?

Which has stronger earnings & valuation, EHAB or GRAL?

Summary

How does Enhabit compare to Heartflow?

Does the media favor HTFL or EHAB?

Do analysts recommend HTFL or EHAB?

Is HTFL or EHAB more profitable?

Which has stronger valuation & earnings, HTFL or EHAB?

Summary

How does Enhabit compare to Definium Therapeutics?

Do institutionals and insiders have more ownership in EHAB or DFTX?

Which has more risk & volatility, EHAB or DFTX?

Do analysts prefer EHAB or DFTX?

Does the media prefer EHAB or DFTX?

Is EHAB or DFTX more profitable?

Which has preferable valuation and earnings, EHAB or DFTX?

Summary

How does Enhabit compare to Addus HomeCare?

Do institutionals & insiders hold more shares of EHAB or ADUS?

Do analysts rate EHAB or ADUS?

Which has preferable valuation & earnings, EHAB or ADUS?

Which has more volatility & risk, EHAB or ADUS?

Does the media favor EHAB or ADUS?

Is EHAB or ADUS more profitable?

Summary

How does Enhabit compare to Surgery Partners?

Which has more risk and volatility, SGRY or EHAB?

Which has preferable valuation and earnings, SGRY or EHAB?

Do analysts rate SGRY or EHAB?

Does the media refer more to SGRY or EHAB?

Is SGRY or EHAB more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EHAB vs. The Competition

Enhabit Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools